HIG1 hypoxia inducible domain family member 1A pseudogene 14Genealiases: []
Q-omics provides the consensus-scored HIGD1AP14 profile across patient tissues and cancer cell-line models. HIGD1AP14 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, HIGD1AP14 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, HIGD1AP14 RNA expression shows 13,768 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight LUAD, KIRC, and DLBC as cancer lineages where HIGD1AP14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIGD1AP14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIGD1AP14 survival associations across molecular data types. HIGD1AP14 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIGD1AP14 RNA expression–survival associations across cancer types. High HIGD1AP14 expression shows unfavorable associations in CHOL, STAD, KIRC, LGG and ACC, but favorable associations in LUAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for HIGD1AP14 RNA expression.
This table summarizes HIGD1AP14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HIGD1AP14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIGD1AP14 shows lower tumor expression in KIRC, READ, THCA and KICH and higher tumor expression in UCEC and BRCA. The KIRC box plot shows higher HIGD1AP14 RNA expression in normal versus tumor tissue (log2 FC = −0.240, t-test p < 0.001).
This table shows molecular features associated with HIGD1AP14 in patient tissues and cancer cell lines. In patient samples, HIGD1AP14 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
